欧洲癌症研究格局图谱:国家与泛欧洲研究与资助的证据基础
该文对2002-2013年Web of Science中EUR31(28个欧盟成员国及冰岛、挪威、瑞士)的癌症研究论文进行文献计量分析,量化各国研究活动、涉及的癌种/研究领域及2009-2013年资助来源。发现EUR31癌症研究论文数与国家GDP高度相关(r²=0.94),但肺癌、食管癌和胰腺癌相对疾病负担研究不足,而中枢神经系统和血液肿瘤获得的支持超过其负担所需;放疗(5%)、姑息治疗(1.2%)和生活质量(0.5%)研究匮乏;
要点
- 肺癌、食管癌和胰腺癌研究相对疾病负担不足,中枢神经系统和血液肿瘤支持超过负担所需。
- 放疗、姑息治疗和生活质量研究占比分别为5%、1.2%和0.5%,明显匮乏。
核心结论
- 多个国家需大幅增加癌症研究产出并调整研究组合以匹配不断增长和变化的癌症负担。
- 资助机构间需更多协调,使资源与科研缺口和临床需求对齐。
- 东欧需发展慈善资助部门,使公众和患者倡导在研究中有积极角色。
研究设计与样本
- 对2002-2013年Web of Science中EUR31(28个欧盟成员国及冰岛、挪威、瑞士)的癌症研究论文进行文献计量分析。
- 量化各国研究活动、涉及的癌种/研究领域及2009-2013年资助来源。
主要发现
- EUR31癌症研究论文数与国家GDP高度相关(r²=0.94)。
- 肺癌、食管癌和胰腺癌研究相对疾病负担不足,中枢神经系统和血液肿瘤支持超过负担所需。
- 放疗、姑息治疗和生活质量研究分别占5%、1.2%和0.5%。
- 西欧/斯堪的纳维亚9国慈善部门研究支出超过政府,东欧慈善研究资助几乎不存在。
临床怎么用
- 国家/超国家癌症研究政策制定可参考癌种与研究领域资助缺口。
- 资助机构可依据疾病负担调整研究资源配置。
- 东欧地区可推动慈善资助发展以补充政府投入。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer research is among the most active biomedical research domains for the European Union (EU). However, little quantitative empirical evidence is available to guide the decisions on the choice of disease site to study, specific research domain focus or allocation of research resources. To inform national/supranational cancer research policy, high-resolution intelligence is needed. METHODS: We performed a bibliometric analysis of European cancer research papers in the Web of Science from 2002 to 2013 to quantify research activity in each of the 28 EU Member States, along with Iceland, Norway and Switzerland (EUR31), which cancer sites/research domains they addressed, and their sources of financial support (2009-2013). FINDINGS: Cancer research papers from EUR31 correlated well with national Gross Domestic Products (r2 = 0.94). However, certain cancer sites (lung, oesophagus and pancreas) were under-researched relative to their disease burden, whereas central nervous system and blood cancers were more generously supported than their burden would warrant. An analysis of research domains indicated a paucity of research on radiotherapy (5%), palliative care (1.2%) and quality of life (0.5%). European cancer research funding in 2012-2013 amounted to ∼€7.6 billion and came from diverse sources, especially in western Europe/Scandinavia, where in nine countries the charitable sector outspent the government but not in Eastern Europe where charitable research funding barely exists. INTERPRETATION: Several countries need to increase their cancer research outputs substantially, and/or alter their research portfolios to better match their growing (and changing) cancer burden. More co-ordination among funding agencies is required, so that resources can be attuned to align activities to research gaps and perceived clinical needs. In Eastern Europe, the charitable funding sector needs to be developed, so that both public and patient advocacy can have an active role in research.
引用
- Begum M, Lewison G, Lawler M, et al. Mapping the European cancer research landscape: An evidence base for national and Pan-European research and funding. Eur J Cancer. 2018. PMID: 30014883. doi:10.1016/j.ejca.2018.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。